International Journal of Urology最新文献

{"title":"Global Adoption of Transcontinental Telesurgery: Are We There Yet?","authors":"Saad Aldousari, Ahmad N Almarzouq, Abdelkareem Hassan, Ahmed Shahin, Abdulrahman H Almazeedi, Basmah Bahbahani","doi":"10.1111/iju.70647","DOIUrl":"10.1111/iju.70647","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":"e70647"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148968771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual Dysfunction and Lower Urinary Tract Dysfunction in Adults With Spina Bifida.","authors":"Daisuke Gotoh, Akira Tachibana, Yuki Oda, Mitsuru Tomizawa, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Yasushi Nakai, Makito Miyake","doi":"10.1111/iju.70635","DOIUrl":"10.1111/iju.70635","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate sexual function and lower urinary tract dysfunction in adults with spina bifida (SB) compared with healthy controls and their impact on quality of life (QOL).</p><p><strong>Methods: </strong>In this prospective observational study, 30 adults with SB (21 women, 9 men) and 28 healthy volunteers (17 women, 11 men) were enrolled (September 2023-December 2024). Sexual and urinary function were assessed with the FSFI, SHIM, IPSS, Overactive Bladder Symptom Score, ICIQ-SF, and King's Health Questionnaire. Group differences were analyzed with Mann-Whitney U or chi-square tests with Benjamini-Hochberg correction; effect sizes were reported as rank-biserial r or Cramér's.</p><p><strong>Results: </strong>Patients with SB had significantly poorer sexual and lower urinary tract function than controls. In women, sexual desire was relatively preserved (q = 0.21, r = 0.20), whereas arousal, lubrication, orgasm, and satisfaction were markedly reduced (all q ≤ 0.003, r = 0.51-0.79). In men, erectile function was severely impaired (SHIM total 3.0 vs. 21.0; q = 0.0006, r = 0.81). IPSS and ICIQ-SF totals were higher in the SB group in both sexes (all q ≤ 0.0004, r ≥ 0.79). IPSS-QOL correlated with ICIQ-SF in both women (Spearman r = 0.57, p = 0.009) and men (r = 0.80, p = 0.011).</p><p><strong>Conclusions: </strong>Adults with SB had substantial sexual and lower urinary tract dysfunction. Sexual desire was relatively preserved in women, whereas urinary incontinence was associated with poorer QOL.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":"e70635"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148968777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Stratification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line Androgen Receptor Pathway Inhibitor-Based Combination Therapy.","authors":"Keiichiro Miyajima, Takafumi Yanagisawa, Wataru Fukuokaya, Ryoko Sakakibara, Naoki Uchida, Marcin Miszczyk, Shota Inoue, Akihiro Matsukawa, Fumihiko Urabe, Keiichiro Mori, Naoki Fujita, Shintaro Narita, Shingo Hatakeyama, Tomonori Habuchi, Shahrokh F Shariat, Takahiro Kimura","doi":"10.1111/iju.70646","DOIUrl":"10.1111/iju.70646","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to stratify clinical risk among patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) treated with first-line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).</p><p><strong>Methods: </strong>We retrospectively analyzed 626 patients with high-volume mHSPC treated with ARPI+ADT between November 2016 and April 2025. A multivariable Cox model for time to castration-resistant prostate cancer (TTCRPC) was developed using nine baseline characteristics, including age, hemoglobin, ECOG performance status, clinical T stage, ISUP grade group, EOD score, lung and liver metastases, and LDH, selected based on clinical relevance and prior evidence. Model discrimination and calibration were assessed using bootstrap internal validation. Patients were stratified into three risk groups based on the linear predictor, and associations with TTCRPC and overall survival (OS) were evaluated.</p><p><strong>Results: </strong>The median follow-up was 34.8 months. Clinical T4 stage, ISUP grade group 5, and higher LDH were independently associated with shorter TTCRPC, whereas lung metastasis was associated with longer TTCRPC. The model had an optimism-corrected C-index of 0.69. TTCRPC differed significantly across the low-, intermediate-, and high-risk groups (p < 0.001); compared with the low-risk group, the HRs were 1.48 (95% CI 1.00-2.17) for the intermediate-risk group and 4.09 (95% CI 2.90-5.77) for the high-risk group. OS also differed significantly across the three risk groups (p < 0.001).</p><p><strong>Conclusions: </strong>In patients with high-volume mHSPC treated with ARPI+ADT, the model showed modest discrimination for TTCRPC and identified groups with different TTCRPC and OS outcomes. These findings suggest the presence of clinically heterogeneous subgroups within high-volume mHSPC and warrant independent validation in external cohorts.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":"e70646"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer","authors":"Tomohiro Hori,&nbsp;Hiroaki Iwamoto,&nbsp;Takahiro Inaba,&nbsp;Ryunosuke Nakagawa,&nbsp;Taiki Kamijima,&nbsp;Hiroshi Kano,&nbsp;Tomoyuki Makino,&nbsp;Renato Naito,&nbsp;Suguru Kadomoto,&nbsp;Hiroshi Yaegashi,&nbsp;Kazuyoshi Shigehara,&nbsp;Takahiro Nohara,&nbsp;Kouji Izumi,&nbsp;Atsushi Mizokami","doi":"10.1111/iju.70627","DOIUrl":"10.1111/iju.70627","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study evaluated and compared the prognostic significance of three different computed tomography (CT)-based radiological indices of sarcopenia—skeletal muscle index (SMI), psoas muscle index (PMI), and three-dimensional (3D) psoas muscle volume index (PVI)—in patients with metastatic castration-sensitive prostate cancer (mCSPC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed 120 patients diagnosed with mCSPC (2003–2022). Baseline muscle parameters were calculated from diagnostic CT scans. Sarcopenia was defined using the Martin criteria for SMI, and optimal cut-offs derived from maximally selected rank statistics for PMI (4.08 cm²/m²) and PVI (92 cm³/m²). Associations of these indices with age, overall survival (OS), and prostate cancer-specific survival (PCSS) were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Advancing age was significantly associated with SMI (OR: 1.05, <i>p</i> = 0.036) and PVI-defined sarcopenia (OR: 1.09, <i>p</i> &lt; 0.001), with a non-significant trend for PMI (OR: 1.06, <i>p</i> = 0.069). Survival analysis revealed that sarcopenia by all three indices was significantly associated with worse OS (SMI [HR: 1.88, <i>p</i> = 0.032], PMI [HR: 2.19, <i>p</i> = 0.016], and PVI [HR: 2.07, <i>p</i> = 0.013]). In multivariable analyzes, SMI (HR: 1.86, <i>p</i> = 0.042), PMI (HR: 3.73, <i>p</i> &lt; 0.001), and PVI (HR: 2.46, <i>p</i> = 0.006) remained independent risk factors for poorer OS. No significant impacts were observed for PCSS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>When using body physique-adjusted or mathematically optimized thresholds, all three easily and rapidly measurable radiological indices (SMI, PMI, and PVI) may serve as potential, independent prognostic indicators for OS in patients with mCSPC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment From Dr. Kato to Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma","authors":"Taigo Kato,&nbsp;Atsuki Matsukawa,&nbsp;Norio Nonomura","doi":"10.1111/iju.70573","DOIUrl":"10.1111/iju.70573","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structured Assessment of Trainee-Performed Transurethral Resection of Bladder Tumors Using the Operative Performance Rating System","authors":"Kana Kohashiguchi,&nbsp;Rikiya Taoka,&nbsp;Hiroyuki Tunemori,&nbsp;Tomoko Honda,&nbsp;Yoichiro Tohi,&nbsp;Mikio Sugimoto","doi":"10.1111/iju.70621","DOIUrl":"10.1111/iju.70621","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment to Validation of the NCCN Subclassification for Intermediate-Risk Prostate Cancer in a Japanese Radical Prostatectomy Cohort: Results From the MICAN Study","authors":"Satoshi Kobayashi","doi":"10.1111/iju.70629","DOIUrl":"10.1111/iju.70629","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148864880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status","authors":"Takuhisa Nukaya,&nbsp;Taku Naiki,&nbsp;Hiromitsu Watanabe,&nbsp;Keita Nakane,&nbsp;Teruo Inamoto,&nbsp;Takahiro Yasui,&nbsp;Takuya Koie,&nbsp;Kiyoshi Takahara","doi":"10.1111/iju.70626","DOIUrl":"10.1111/iju.70626","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Metastatic castration-resistant prostate cancer has a poor prognosis. Although olaparib has demonstrated efficacy in patients with <i>BRCA1/2</i> mutations, real-world data in Japanese patients remain limited. We aimed to evaluate the efficacy and safety of olaparib in patients with BRCA-mutated metastatic castration-resistant prostate cancer and explore the association of <i>BRCA2</i> loss and microsatellite instability status with treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter retrospective study of 34 patients with BRCA-mutated metastatic castration-resistant prostate cancer treated with olaparib between December 2020 and December 2024. The primary endpoint was progression-free survival. Secondary endpoints included overall survival, prostate-specific antigen-50 response rate, and safety. Exploratory analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 34 patients, 33 had a <i>BRCA2</i> mutation and one had a <i>BRCA1</i> mutation. Prostate-specific antigen reduction was observed in 76.4% of patients; prostate-specific antigen-50 response rate was 58.8%. Median progression-free and overall survival were 15.8 and 35.1 months, respectively. Grade ≥ 3 adverse events (most commonly anemia) occurred in 17.6% of patients. Treatment discontinuation due to adverse events occurred in one patient. Exploratory analyses were performed in 23 <i>BRCA2</i>-mutated patients who underwent comprehensive genomic profiling. <i>BRCA2</i> loss was observed in 39.1% of patients and showed a trend toward prolonged progression-free survival, whereas microsatellite instability-high status was observed in 13.0% and was associated with shorter progression-free survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Olaparib demonstrated efficacy and safety in Japanese patients with BRCA-mutated metastatic castration-resistant prostate cancer. Exploratory analyses revealed that <i>BRCA2</i> loss may be associated with prolonged progression-free survival, whereas microsatellite instability-high status may be associated with shorter progression-free survival. These findings require validation in larger cohorts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment to Feasibility and Safety of Repeat Robot-Assisted Partial Nephrectomy for Ipsilateral Local Recurrence: A Case Series","authors":"Kazuhiko Yoshida,&nbsp;Toshio Takagi","doi":"10.1111/iju.70628","DOIUrl":"https://doi.org/10.1111/iju.70628","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment to Preoperative Tumor Shape Irregularity Is Associated With Pathological Upstaging to pT3 in Clinical T1 Renal Cell Carcinoma Treated With Partial or Radical Nephrectomy","authors":"Hajime Tanaka,&nbsp;Yasuhisa Fujii","doi":"10.1111/iju.70613","DOIUrl":"10.1111/iju.70613","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}